Filings & corporate actions
40 results filed
CSVNext results · Q2 FY27
Expected 20 Oct 2026 – 12 Nov 2026
Estimate: filed 20–43 days after quarter end, last 5 times
Dividend
₹7.21 per share · last 29 May 2026
2026
- 29 JulresultsResults · Q1 FY27 · consolidated and standalone+2.6%NSE
- 18 JulshareholdingShareholding · 30 Jun 2026+0.5%NSE
- 29 MaydividendDividend · ₹7.21 per share+3.6%
- 20 MayresultsResults · Q4 FY26 · consolidated and standalone-5.0%NSE
- 15 AprshareholdingShareholding · 31 Mar 2026+4.4%NSE
- 13 FebresultsResults · Q3 FY26 · consolidated and standalone-3.5%NSE
- 15 JanshareholdingShareholding · 31 Dec 2025-1.4%NSE
Reaction to results · all yearsrose on day 0 in 15 of 39 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 29 Jul 2026 | +2.6% | -1.1% | -5.8% | 5.1× |
| Q4 FY26 | 20 May 2026 | -5.0% | -4.1% | -0.7% | 3.8× |
| Q3 FY26 | 13 Feb 2026 | -3.5% | -4.4% | -9.5% | 2.8× |
| Q2 FY26 | 12 Nov 2025 | -3.6% | +6.0% | +1.0% | 1.3× |
| Q1 FY26 | 5 Aug 2025 | +0.3% | -6.9% | -2.2% | 3.2× |
| Q4 FY25 | 19 May 2025 | +1.8% | +8.8% | +23.8% | 1.5× |
| Q3 FY25 | 5 Feb 2025 | +12.9% | +5.7% | +3.1% | 23.9× |
| Q2 FY25 | 25 Oct 2024 | -0.9% | +2.0% | +13.7% | 0.2× |
| Q1 FY25 | 3 Aug 2024 | -3.8% | +7.6% | +29.8% | 0.7× |
| Q4 FY24 | 22 May 2024 | -2.5% | +0.6% | +14.9% | 2.1× |
| Q3 FY24 | 14 Feb 2024 | -1.1% | +0.3% | -0.3% | 1.0× |
| Q2 FY24 | 9 Nov 2023 | +1.6% | +1.0% | -2.4% | 15.2× |
| Q1 FY24 | 7 Aug 2023 | -2.2% | -2.2% | +0.1% | 0.3× |
| Q4 FY23 | 18 May 2023 | -1.2% | -2.3% | +2.4% | 2.2× |
| Q3 FY23 | 18 Jan 2023 | -3.0% | -4.2% | -1.0% | 2.0× |
| Q2 FY23 | 20 Oct 2022 | -2.9% | -0.5% | -7.0% | 2.0× |
| Q1 FY23 | 5 Aug 2022 | +0.4% | +0.1% | +1.7% | 0.6× |
| Q4 FY22 | 4 May 2022 | -1.9% | -1.2% | -0.7% | 1.6× |
| Q3 FY22 | 28 Jan 2022 | +0.3% | +1.1% | -3.0% | 1.1× |
| Q2 FY22 | 30 Oct 2021 | -0.9% | -3.3% | -10.8% | 0.4× |
| Q1 FY22 | 29 Jul 2021 | +2.5% | -3.1% | -5.6% | 4.2× |
| Q4 FY21 | 14 May 2021 | +2.5% | +8.4% | +7.9% | 1.4× |
| Q3 FY21 | 28 Jan 2021 | -2.8% | -7.3% | -5.9% | 0.7× |
| Q2 FY21 | 4 Nov 2020 | +1.5% | -0.9% | +4.4% | 0.5× |
| Q1 FY21 | 4 Aug 2020 | +5.9% | +9.7% | -4.7% | 1.2× |
| Q4 FY20 | 27 Jun 2020 | 0.0% | -2.6% | -9.3% | 0.5× |
| Q3 FY20 | 15 Feb 2020 | -5.1% | -9.3% | -16.6% | 2.8× |
| Q2 FY20 | 8 Nov 2019 | -2.1% | -3.1% | +14.9% | 0.7× |
| Q1 FY20 | 27 Jul 2019 | -1.6% | +2.2% | -6.5% | 5.5× |
| Q4 FY19 | 22 May 2019 | -6.3% | -13.2% | -17.5% | 20.6× |
| Q3 FY19 | 31 Jan 2019 | +2.8% | +4.4% | -2.8% | 3.5× |
| Q2 FY19 | 20 Nov 2018 | -0.4% | +0.1% | +10.9% | 2.0× |
| Q1 FY19 | 24 Aug 2018 | +3.4% | +9.9% | +15.8% | 2.7× |
| Q4 FY18 | 25 Jun 2018 | +1.8% | -2.7% | +9.0% | 1.0× |
| Q3 FY17 | 2 Apr 2018 | +0.1% | -0.7% | -2.1% | 0.2× |
| Q3 FY18 | 16 Mar 2018 | -1.1% | -4.7% | -3.3% | 9.5× |
| Q2 FY17 | 23 Nov 2017 | -2.6% | +24.8% | +20.3% | 1.1× |
| Q2 FY18 | 23 Nov 2017 | -2.6% | +24.8% | +20.3% | 1.1× |
| Q1 FY18 | 1 Sept 2017 | -0.9% | +0.6% | -0.9% | 0.2× |
| Average | -0.4% | +1.0% | +1.9% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+13.0%
Profit YoY+14.6%
Interest cost YoY-13.2%
Revenue QoQ+15.4%
Profit QoQ-48.6%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +19.5% | +22.6% | — | +20.6% | +19.8% | +18.1% |
| Profit | +30.2% | +21.1% | — | +12.3% | +14.1% | +11.9% |
Key data
CSVOpen1,188.60
Day range1,175.00 – 1,201.30
52-week range1,162.90 – 1,740.00
From 52w high-31.9%
RSI (14)22.1
ATR (14)39.03
Volume47.5K
Avg volume (20D)90.9K
Rel volume0.52×
Volatility (1Y)29.7%
Turnover₹5.6Cr
SMA 50 / 2001,320.58 / 1,384.69
Delivery percentage
Latest · 6 Oct 202657.1%
20-day avg52.7%
1-year avg56.0%
Percentile (own history)66th
Range9.5–97.8%
Sessions1,731
Over the last 20 sessions ERIS settled 52.7% of its traded quantity, which is above average for an NSE equity. Its one-year average is 56.0%, so recent sessions are running 3.2 points lower than usual. The latest session ranks higher than 66% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -0.33% | -4.17% | -9.11% | -17.45% | -11.07% | -25.28% |
Valuation
CSVMarket cap₹16,436 Cr
P/E (TTM)24.7
EPS (TTM)47.98
Shares outstanding13.86Cr
Listed29 Jun 2017
Ownership
CSVPromoter54.14%
Promoter Δ QoQ+0.22 pp
Public45.86%
FII5.75%
DII20.72%
Pledged16.85%
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 792.4 | 807.5 | 756.6 | 873.3 |
| YoY chg | +7.2% | +11.0% | +7.3% | +13.0% |
| Net profit (₹ Cr) | 134.5 | 108.8 | 279.1 | 143.3 |
| YoY chg | +39.6% | +25.2% | +172.7% | +14.6% |
| Net margin | 17.0% | 13.5% | 36.9% | 16.4% |
| EPS | 8.81 | 7.31 | 20.57 | 10.26 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 54.14% · public 45.86%2017-062026-06
- Promoter
- Public and others
- Promoter
- 54.14%
- Public
- 45.86%
- Promoter change
- +0.22 pp
- Filed
- 18 Jul 2026
- FII
- 5.75%
- DII
- 20.72%
- Promoter pledged
- 16.85%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 505.3 | 486.3 | 550.9 | 719.7 | 739.0 | 727.5 | 705.3 | 773.0 | 792.4 | 807.5 | 756.6 | 873.3 | |
| Other income | 3.5 | 4.2 | 15.1 | 1.6 | 6.8 | 4.2 | 8.0 | 2.7 | 2.8 | 0.0 | 2.2 | 2.4 | |
| Total income | 508.8 | 490.5 | 566.1 | 721.4 | 745.7 | 731.7 | 713.3 | 775.7 | 795.2 | 807.5 | 758.8 | 875.6 | |
| Total expenses | 382.5 | 374.6 | 489.4 | 606.0 | 616.6 | 615.5 | 584.4 | 615.5 | 622.8 | 645.0 | 598.2 | 695.8 | |
| └ Finance costs | 16.3 | 18.1 | 33.0 | 60.4 | 59.5 | 57.2 | 54.3 | 48.7 | 49.6 | 48.8 | 45.6 | 46.7 | |
| └ Depreciation | 42.1 | 45.7 | 53.9 | 75.9 | 80.5 | 81.2 | 77.3 | 70.5 | 69.1 | 70.3 | 69.6 | 72.1 | |
| Profit before tax | 126.2 | 115.9 | 76.6 | 115.3 | 129.1 | 116.2 | 128.8 | 160.2 | 172.4 | 145.2 | 160.6 | 179.9 | |
| Tax expense | 3.9 | 14.4 | (3.0) | 25.9 | 32.8 | 29.2 | 26.5 | 36.0 | 38.2 | 36.5 | (119.7) | 36.2 | |
| Net profit | 122.3 | 101.5 | 79.6 | 89.4 | 96.4 | 86.9 | 102.4 | 125.1 | 134.5 | 108.8 | 279.1 | 143.3 | |
| EPS | 9.08 | 7.55 | 5.22 | 6.11 | 6.73 | 6.15 | 6.90 | 8.66 | 8.82 | 7.32 | 20.60 | 10.28 | |
| Net margin | 24.21% | 20.86% | 14.45% | 12.42% | 13.04% | 11.95% | 14.51% | 16.18% | 16.97% | 13.48% | 36.89% | 16.41% | |
| PBT margin | 24.98% | 23.83% | 13.91% | 16.02% | 17.47% | 15.97% | 18.26% | 20.73% | 21.76% | 17.99% | 21.23% | 20.60% | |
| Tax rate | 3.11% | 12.44% | -3.90% | 22.46% | 25.37% | 25.17% | 20.59% | 22.47% | 22.16% | 25.15% | -74.52% | 20.11% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 29 Jul 2026.
ERIS at a glance
- ERIS closed at ₹1,184.7 on 6 Oct 2026, -0.33% on the day, -25.3% over one year, 31.9% below its 52-week high of ₹1,740.
- Delivery was 57.1% of traded quantity on 6 Oct 2026, the 66th percentile of its own 1,731 sessions with a reading (20-session average 52.7%, 1-year average 56.0%).
- Market capitalisation is ₹16,436 crore at a trailing P/E of 24.7 (trailing EPS ₹47.98).
- Q1 FY27 results (consolidated, filed 29 Jul 2026): revenue ₹873 crore (+13.0% year on year), net profit ₹143 crore (+14.6%); the price moved +2.6% on the first session after.
- Promoters held 54.14% at 30 Jun 2026, up 0.22 percentage points on the previous filing, with 16.85% of promoter shares pledged.
- Q2 FY27 results are expected between 20 Oct 2026 and 12 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE406M01024
SeriesEQ
Listed29 Jun 2017
History from29 Jun 2017
Sessions2,294
Turnover rank#985
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE